An artificial pancreas for automated blood glucose control in patients with Type 1 diabetes

Therapeutic Delivery

Volumn 6, Issue 5, 2015, Pages 211-221

  Schmidt, Signe ^a,b   Boiroux, Dimitri ^b,c   Ranjan, Ajenthen ^a,b   Jørgensen, John Bagterp ^c   Madsen, Henrik ^c   Nørgaard, Kirsten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Danish Diabetes Academy   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HYALURONIDASE; INSULIN; PRAMLINTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ALGORITHM; ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; CLINICAL STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DELIVERY DEVICE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE SENSOR; HEART RATE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; INSULIN SENSITIVITY; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 1; QUALITY OF LIFE;

ALGORITHMS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 1; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL; QUALITY OF LIFE;

EID: 84929748840     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.15.12     Document Type: Review

References (74)

1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 383(9911), 69-82 (2014).
2. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329(14), 977-986 (1993).
3. Nathan DM, Cleary PA, Backlund JYC et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. 353(25), 2643-2653 (2005).
4. Nørgaard K, Scaramuzza A, Bratina N et al. Routine sensor-augmented pump therapy in Type 1 diabetes: The INTERPRET Study. Diabetes Technol. Ther. 15(4) (2013).
5. Basu A, Dube S, Slama M et al. Time lag of glucose from intravascular to interstitial compartment in humans. Diabetes 62(12), 4083-4087 (2013).
6. Hansen AH, Duun-Henriksen AK, Juhl R et al. Predicting plasma glucose from interstitial glucose observations using Bayesian methods. J. Diabetes Sci. Technol. 8(2), 321-330 (2014).
7. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling beta-cell insulin secretion-implications for closed-loop glucose homeostasis. Diabetes Technol. Ther. 5(6), 953-964 (2003).
8. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes 60(11), 2672-2682 (2011).
9. Duun-Henriksen AK, Schmidt S, Røge RM et al. Model identification using stochastic differential equation grey-box models in diabetes. J. Diabetes Sci. Technol. 7(2), 431-440 (2013).
10. Van Dijk PR, Logtenberg SJJ, Gans ROB, Bilo HJG, Kleefstra N. Intraperitoneal insulin infusion: treatment option for Type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. Clin. Endocrinol. 81(4), 488-497 (2014).
11. Dassau E, Zisser H, C Palerm C, A Buckingham B, Jovanovic L, J Doyle F. Modular artificial beta-cell system: a prototype for clinical research. J. Diabetes Sci. Technol. 2(5), 863-872 (2008).
12. Kovatchev BP, Renard E, Cobelli C et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 37(7), 1789-1796 (2014).
13. Van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JBL, Devries JH. Feasibility of a portable bihormonal closedloop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol. Ther. 16(3), 131-136 (2014).
14. Leelarathna L, Dellweg S, Mader JK et al. Day and night home closed-loop insulin delivery in adults with Type 1 diabetes: three-center randomized crossover study. Diabetes Care 37(7), 1931-1937 (2014).
15. Russell SJ, El-Khatib FH, Sinha M et al. Outpatient glycemic control with a bionic pancreas in Type 1 diabetes. N. Engl. J. Med. 371(4), 313-325 (2014).
16. Novo Nordisk. NovoLog® (insulin aspart [rDNA origin] injection). www.novo-pi.com/novolog.pdf
17. Schmidt S, Finan DA, Duun-Henriksen AK et al. Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated Type 1 diabetes: collection of clinical data for glucose modeling. Diabetes Technol. Ther. 14(3), 210-217 (2012)
18. Van Bon AC, Verbitskiy E, von Basum G, Hoekstra JBL, DeVries JH. Exercise in closed-loop control: a major hurdle. J. Diabetes Sci. Technol. 5(6), 1337-1341 (2011).
19. Matuleviciene V, Joseph J, Andelin M et al. A clinical trial of the accuracy and treatment experience of the Dexcom G4 Sensor (Dexcom G4 System) and Enlite Sensor (Guardian REAL-Time System) tested simultaneously in ambulatory patients with Type 1 diabetes. Diabetes Technol. Ther. 16(11), 1-9 (2014).
20. Helton KL, Ratner BD, Wisniewski NA. Biomechanics of the sensor-tissue interface-effects of motion, pressure, and design on sensor performance and foreign body response-part II: examples and application. J. Diabetes Sci. Technol. 5(3), 647-656 (2011).
21. Damiano ER, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care 36(2), 251-259 (2013).
22. Damiano ER, McKeon K, El-Khatib FH, Zheng H, Nathan DM, Russell SJ. A comparative effectiveness analysis of three continuous glucose monitors: the Navigator, G4 Platinum, and Enlite. J. Diabetes Sci. Technol. 8(4), 699-708 (2014).
23. Patel PJ, Benasi K, Ferrari G et al. Randomized trial of infusion set function: steel versus teflon. Diabetes Technol. Ther. 16(1), 15-19 (2014).
24. Pickup J, Viberti GC, Bilous RW et al. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia 22(3), 175-179 (1982).
25. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with Type 1 diabetes using an artificial pancreas. Diabetes Care 31(5), 934-939 (2008).
26. The Doyle Group. Artificial Pancreas Clinical Database. www.thedoylegroup.org
27. Schmidt S, Schelde B, Nørgaard K. Effects of advanced carbohydrate counting in patients with Type 1 diabetes: a systematic review. Diabet. Med. 31(8), 886-896 (2014).
28. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for Type 1 diabetes. Sci. Transl. Med. 2(27), 27ra27 (2010).
29. Castle JR, Engle JM, El Youssef J et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 33(6), 1282-1287 (2010).
30. Van Bon AC, Jonker LD, Koebrugge R, Koops R, Hoekstra JBL, Devries JH. Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions. J. Diabetes Sci. Technol. 6(5), 1114-1122 (2012).
31. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol. 8587(14), 1-10 (2014).
32. Reiband HK, Schmidt S, Ranjan A, Holst JJ, Madsbad S, Nørgaard K. Dual-hormone treatment with insulin and glucagon in patients with type 1 diabetes mellitus. Diabetes. Metab. Res. Rev. doi:10.1002/dmrr.2632 (2014) (Epub ahead of print).
33. Ward WK, Castle JR, El Youssef J. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia. J. Diabetes Sci. Technol. 5(6), 1373-1380 (2011).
34. Pohl R, Li M, Krasner A, De Souza E. Development of stable liquid glucagon formulations for use in artificial pancreas. J. Diabetes Sci. Technol. 9(1), 8-16 (2015).
35. Newswanger B, Ammons S, Phadnis N et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J. Diabetes Sci. Technol. 9(1), 24-33 (2015).
36. Weinzimer S a, Sherr JL, Cengiz E et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with Type 1 diabetes. Diabetes Care 35(10), 1994-1999 (2012).
37. Renukuntla VS, Ramchandani N, Trast J, Cantwell M, Heptulla RA. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in Type 1 diabetes in a closed loop setting with ePID algorithm. J. Diabetes Sci. Technol. (2014).
38. Garg SK, Michels AW, Shah VN. Use of non-insulin therapies for Type 1 diabetes. Diabetes Technol. Ther. 15(11), 901-908 (2013).
39. Breton MD, Brown SA, Karvetski CH et al. Adding heart rate signal to a control-to-range artificial pancreas system improves the protection against hypoglycemia during exercise in Type 1 diabetes. Diabetes Technol. Ther. 16(8), 506-511 (2014).
40. Kovatchev BP, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of Type 1 diabetes. J. Diabetes Sci. Technol. 3(1), 44-55 (2009).
41. Man CD, Micheletto F, Lv D, Breton M, Kovatchev B, Cobelli C. The UVA/PADOVA Type 1 diabetes simulator: new features. J. Diabetes Sci. Technol. 8(1), 26-34 (2014).
42. Man CD, Rizza R, Cobelli C. Meal simulation model of the glucose-insulin system. IEEE Trans. Biomed. Eng. 54(10), 1740-1749 (2007).
43. Schiavon M, Dalla Man C, Kudva YC, Basu A, Cobelli C. In silico optimization of basal insulin infusion rate during exercise: implication for artificial pancreas. J. Diabetes Sci. Technol. 7(6), 1461-1469 (2013).
44. Patek S, Bequette BW, Breton M et al. In silico preclinical trials: methodology and engineering guide to closed-loop control in Type 1 diabetes mellitus. J. Diabetes Sci. Technol. 3(2), 269-282 (2009).
45. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of Type 1 diabetes. Diabetes 55(12), 3344-3350 (2006).
46. Hovorka R, Kumareswaran K, Harris J et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with Type 1 diabetes: crossover randomised controlled studies. BMJ 342, d1855 (2011).
47. Breton M, Farret A, Bruttomesso D et al. Fully integrated artificial pancreas in Type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 61(9), 2230-2237 (2012).
48. Kovatchev B, Cobelli C, Renard E et al. Multinational study of subcutaneous model-predictive closed-loop control in Type 1 diabetes mellitus: summary of the results. J. Diabetes Sci. Technol. 4(6), 1374-1381 (2010).
49. El Youssef J, Castle JR, Branigan DL et al. A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in Type 1 diabetes. J. Diabetes Sci. Technol. 5(6), 1312-1326 (2011).
50. Schmidt S, Boiroux D, Duun-Henriksen AK et al. Model-based closed-loop glucose control in Type 1 diabetes: the DiaCon experience. J. Diabetes Sci. Technol. 7(5), 1255-1264 (2013).
51. Haidar A, Legault L, Dallaire M et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with Type 1 diabetes: a randomized crossover controlled trial. CMAJ 185(4), 297-305 (2013).
52. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in Type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 35(11), 2148-2155 (2012).
53. Mauseth R, Hirsch IB, Bollyky J et al. Use of a "fuzzy logic" controller in a closed-loop artificial pancreas. Diabetes Technol. Ther. 15(8), 628-633 (2013).
54. Chase HP, Doyle FJ, Zisser H et al. Multicenter closed-loop/hybrid meal bolus insulin delivery with Type 1 diabetes. Diabetes Technol. Ther. 16(10), 623-632 (2014).
55. Dauber A, Corcia L, Safer J, Agus MSD, Einis S, Steil GM. Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. Diabetes Care 36(2), 222-227 (2013).
56. Sherr JL, Cengiz E, Palerm CC et al. Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in Type 1 diabetes. Diabetes Care 36(10), 2909-2914 (2013).
57. Elleri D, Allen JM, Nodale M et al. Automated overnight closed-loop glucose control in young children with Type 1 diabetes. Diabetes Technol. Ther. 13(4), 419-424 (2011).
58. Nimri R, Danne T, Kordonouri O et al. The "Glucositter"overnight automated closed loop system for Type 1 diabetes: a randomized crossover trial. Pediatr. Diabetes 14(3), 159-167 (2013).
59. Hovorka R, Allen JM, Elleri D et al. Manual closed-loop insulin delivery in children and adolescents with Type 1 diabetes: a Phase 2 randomised crossover trial. Lancet 375(9716), 743-751 (2010).
60. Murphy HR, Kumareswaran K, Elleri D et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with Type 1 diabetes: a randomized crossover case series. Diabetes Care 34(12), 2527-2529 (2011).
61. Murphy HR, Elleri D, Allen JM et al. Closed-loop insulin delivery during pregnancy complicated by Type 1 diabetes. Diabetes Care 34(2), 406-411 (2011).
62. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 33(1), 121-127 (2010).
63. O'Grady MJ, Retterath AJ, Keenan DB et al. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with Type 1 diabetes. Diabetes Care 35(11), 2182-2187 (2012).
64. Elleri D, Allen JM, Biagioni M et al. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with Type 1 diabetes. Pediatr. Diabetes 13(6), 449-453 (2012).
65. Cobelli C, Renard E, Kovatchev B et al. Pilot studies of wearable outpatient artificial pancreas in Type 1 diabetes. Diabetes Care 35, e65-67 (2012).
66. Phillip M, Battelino T, Atlas E et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N. Engl. J. Med. 368(9), 824-833 (2013).
67. Ly TT, Breton MD, Keith-Hynes P et al. Overnight glucose control with an automated, unified safety system in children and adolescents with Type 1 diabetes at diabetes camp. Diabetes Care 37(8), 2310-2316 (2014).
68. Hovorka R, Elleri D, Thabit H et al. Overnight closed-loop insulin delivery in young people with Type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 37(5), 1204-1211 (2014).
69. Thabit H, Lubina-Solomon A, Stadler M et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with Type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol. 2(9), 701-709 (2014).
70. Nimri R, Muller I, Atlas E et al. MD-logic overnight control for 6 weeks of home use in patients with Type 1 diabetes: randomized crossover trial. Diabetes Care 37(11), 3025-3032 (2014).
71. Leelarathna L, Dellweg S, Mader JK et al. Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled Type 1 diabetes: a randomised crossover study protocol. BMJ Open 4(9), e006075 (2014).
72. Van Bon AC, Brouwer TB, von Basum G, Hoekstra JBL, DeVries JH. Future acceptance of an artificial pancreas in adults with Type 1 diabetes. Diabetes Technol. Ther. 13(7), 731-736 (2011).
73. Barnard KD, Wysocki T, Allen JM et al. Closing the loop overnight at home setting: psychosocial impact for adolescents with Type 1 diabetes and their parents. BMJ Open Diabetes Res. Care 2(1), e000025 (2014).
74. Luijf YM, DeVries JH, Zwinderman K et al. Day and night closed-loop control in adults with Type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care 36(12), 3882-3887 (2013).